Amarin Mails Letter to Shareholders Highlighting New Board and Superior Leadership
Significantly Refreshed Board Overseeing Successful Execution of Amarin’s Transformation Plan to Drive Short- and Long-Term Value; Outmatches Sarissa’s Slate in Every Critical Area
Related news for (AMRN)
- Amarin Chairman & CEO Issue Letter to Shareholders
- Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
- Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
- Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
- Sarissa Capital Urges Amarin Shareholders to Vote “FOR” Necessary Change